EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improvement of Spontaneous Locomotor Activity in a Murine Model of Duchenne Muscular Dystrophy by N‐Acetylglucosamine Alone and in Combination With Prednisolone

Masahiko S Satoh, Guillaume St-Pierre, Ann Rancourt, Maude Fillion, Sachiko Sato iD

The FASEB Journal · 2025

DOI: 10.1096/fj.202500196r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Masahiko S Satoh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of DNA Damage Responses and Bioimaging, Research Centre of CHU de Quebec and Axis of Oncology, Faculty of Medicine, Laval University, Queb…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Prednisolone, Acetylglucosamine, Motor Activity. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Government | CIHR | Institute of Musculoskeletal Health and Arthritis (IALA), Defeat Duchenne Canada, UofA | Canadian Glycomics Network (GlycoNet).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N‐acetylglucosamine (GlcNAc) is an endogenous compound with intracellular concentration closely linked to the biosynthesis of acetyllactosamine‐rich N‐linked oligosaccharides. These oligosaccharides interact with mammalian lectin galectin‐3, mediating cell surface receptor dynamics as well as cell–cell and cell‐extracellular matrix interactions. Our previous and recent studies suggest that GlcNAc, in conjunction with galectin‐3, enhances muscle regeneration in vitro. We have also demonstrated that intraperitoneal GlcNAc administration improves muscle strength in mdx mice, a murine model of Duchenne muscular dystrophy (DMD). Here, we show that oral administration of GlcNAc significantly improves the spontaneous locomotor activity of mdx mice. Daily treatment with United States Pharmacopeia‐grade GlcNAc at doses of 0.6, 1.2, 1.8, and 2.4 g/kg body weight for 35 days significantly enhanced nocturnal spontaneous locomotor activity, with the 1.2 g/kg body weight dose (equivalent to 0.144 g/kg body weight in humans) reducing damages of extensor digitorum longus muscle by nearly 50%. Although consecutive forced exercises, specifically horizontal and downhill treadmill running, reduced GlcNAc‐mediated improvement, mice treated with 0.6 and 1.2 g/kg body weight still showed increased overall spontaneous locomotor activity under this condition, despite the lack of protection against repeated eccentric contraction‐induced injury. These findings suggest that GlcNAc enhances overall muscle health, possibly through mechanisms other than direct protection from muscle injury. One possible contributing mechanism may involve enhanced muscle repair or regeneration, as suggested by our related in vitro myogenesis work. Notably, co‐administration of GlcNAc with prednisolone, a corticosteroid commonly prescribed for DMD patients, further enhanced spontaneous locomotor improvement in mdx mice compared to prednisolone alone. These findings suggest that GlcNAc has the potential to improve the clinical status of DMD patients, either as a monotherapy or in combination with corticosteroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchennePrednisoloneAcetylglucosamineMotor ActivityAnimalsMiceMice, Inbred mdxDisease Models, AnimalMaleMice, Inbred C57BLDrug Therapy, CombinationMuscle, Skeletal

Substanzen

PrednisoloneAcetylglucosamine

Autor:innen und Institutionen

  • Laboratory of DNA Damage Responses and Bioimaging, Research Centre of CHU de Quebec and Axis of Oncology, Faculty of Medicine, Laval University, Quebec, Canada.
  • Glycobiology and Bioimaging Laboratory of Research Center for Infectious Diseases and Axis of Infectious and Immunological Diseases, Research Centre of CHU de Quebec, Faculty of Medicine, Laval University, Quebec, Canad…

ORCID-Profile: Sachiko Sato

Förderung

  • Canadian Government | CIHR | Institute of Musculoskeletal Health and Arthritis (IALA)
  • Defeat Duchenne Canada
  • UofA | Canadian Glycomics Network (GlycoNet)
  • Canada Foundation for Innovation (CFI)
  • Institute of Musculoskeletal Health and Arthritis
  • Canadian Glycomics Network

Zitieren

APA

Satoh, M. S., St-Pierre, G., Rancourt, A., Fillion, M., & Sato, S. (2025). Improvement of Spontaneous Locomotor Activity in a Murine Model of Duchenne Muscular Dystrophy by N‐Acetylglucosamine Alone and in Combination With Prednisolone. The FASEB Journal. https://doi.org/10.1096/fj.202500196r

Vancouver

Satoh MS, St-Pierre G, Rancourt A, Fillion M, Sato S. Improvement of Spontaneous Locomotor Activity in a Murine Model of Duchenne Muscular Dystrophy by N‐Acetylglucosamine Alone and in Combination With Prednisolone. The FASEB Journal. 2025. doi:10.1096/fj.202500196r

BibTeX
@article{Satoh2025,
  author = {Satoh, Masahiko S and St-Pierre, Guillaume and Rancourt, Ann and Fillion, Maude and Sato, Sachiko},
  title = {Improvement of Spontaneous Locomotor Activity in a Murine Model of Duchenne Muscular Dystrophy by N‐Acetylglucosamine Alone and in Combination With Prednisolone},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202500196r}
}
Kostenlos starten →